Lewy Body Disorders

Disease

Related News

CSF DOPA Decarboxylase Biomarker Shows Strong Diagnostic Potential for Lewy Body Disorders

Jun 07, 2026

A new cerebrospinal fluid biomarker for DOPA decarboxylase (DDC) shows strong diagnostic potential for Lewy body disorders including Parkinson's disease and dementia with Lewy bodies. Validated across multiple cohorts, CSF DDC levels were significantly elevated in these conditions with high diagnostic accuracy. The biomarker correlated with alpha-synuclein pathology but plasma levels showed no diagnostic value.

DOPA Decarboxylase Biomarker Improves Diagnosis of Parkinson's and Lewy Body Dementia

Mar 25, 2026

Researchers have identified DOPA decarboxylase as a quantitative biomarker in cerebrospinal fluid that improves diagnosis of Parkinson's disease and Lewy body dementia. The protein levels are up to 2.5 times higher in affected patients and can differentiate these conditions from Alzheimer's disease. The discovery provides clinicians with an objective diagnostic tool for conditions that are frequently misdiagnosed due to overlapping symptoms.